Breast Cancer - Pipeline Review, H1 2015


#244729

2317pages

Global Markets Direct

$ 2500

In Stock

 

Global Markets Directs, Breast Cancer Pipeline Review, H1 2015, provides an overview of the Breast Cancers therapeutic pipeline.

 

This report provides comprehensive information on the therapeutic development for Breast Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Breast Cancer and special features on late-stage and discontinued projects.

 

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

 

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

 

Scope

 

  • The report provides a snapshot of the global therapeutic landscape of Breast Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Breast Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Breast Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

 

Reasons to buy

 

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Breast Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Breast Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Table of Contents 2

 

Introduction 16
Breast Cancer Overview 17
Therapeutics Development 18
Breast Cancer - Therapeutics under Development by Companies 20
Breast Cancer - Therapeutics under Investigation by Universities/Institutes 51
Breast Cancer - Pipeline Products Glance 60
Breast Cancer - Products under Development by Companies 64
Breast Cancer - Products under Investigation by Universities/Institutes 111
Breast Cancer - Companies Involved in Therapeutics Development 122
Breast Cancer - Therapeutics Assessment 468
Drug Profiles 510
Breast Cancer - Recent Pipeline Updates 1716
Breast Cancer - Dormant Projects 2169
Breast Cancer - Discontinued Products 2208
Breast Cancer - Product Development Milestones 2219
 

Appendix 2231

 

Number of Products under Development for Breast Cancer, H1 2015 103

Number of Products under Development for Breast Cancer - Comparative Analysis, H1 2015 104

Number of Products under Development by Companies, H1 2015 106

Number of Products under Development by Companies, H1 2015 (Contd..1) 107

Number of Products under Development by Companies, H1 2015 (Contd..2) 108

Number of Products under Development by Companies, H1 2015 (Contd..3) 109

Number of Products under Development by Companies, H1 2015 (Contd..4) 110

Number of Products under Development by Companies, H1 2015 (Contd..5) 111

Number of Products under Development by Companies, H1 2015 (Contd..6) 112

Number of Products under Development by Companies, H1 2015 (Contd..7) 113

Number of Products under Development by Companies, H1 2015 (Contd..8) 114

Number of Products under Development by Companies, H1 2015 (Contd..9) 115

Number of Products under Development by Companies, H1 2015 (Contd..10) 116

Number of Products under Development by Companies, H1 2015 (Contd..11) 117

Number of Products under Development by Companies, H1 2015 (Contd..12) 118

Number of Products under Development by Companies, H1 2015 (Contd..13) 119

Number of Products under Development by Companies, H1 2015 (Contd..14) 120

Number of Products under Development by Companies, H1 2015 (Contd..15) 121

Number of Products under Development by Companies, H1 2015 (Contd..16) 122

Number of Products under Development by Companies, H1 2015 (Contd..17) 123

Number of Products under Development by Companies, H1 2015 (Contd..18) 124

Number of Products under Development by Companies, H1 2015 (Contd..19) 125

Number of Products under Development by Companies, H1 2015 (Contd..20) 126

Number of Products under Development by Companies, H1 2015 (Contd..21) 127

Number of Products under Development by Companies, H1 2015 (Contd..22) 128

Number of Products under Development by Companies, H1 2015 (Contd..23) 129

Number of Products under Development by Companies, H1 2015 (Contd..24) 130

Number of Products under Development by Companies, H1 2015 (Contd..25) 131

Number of Products under Development by Companies, H1 2015 (Contd..26) 132

Number of Products under Development by Companies, H1 2015 (Contd..27) 133

Number of Products under Development by Companies, H1 2015 (Contd..28) 134

Number of Products under Development by Companies, H1 2015 (Contd..29) 135

Number of Products under Investigation by Universities/Institutes, H1 2015 137

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 138

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 139

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..3) 140

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..4) 141

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..5) 142

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..6) 143

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..7) 144

Comparative Analysis by Late Stage Development, H1 2015 145

Comparative Analysis by Clinical Stage Development, H1 2015 146

Comparative Analysis by Early Stage Development, H1 2015 147

Comparative Analysis by Unknown Stage Development, H1 2015 148

Products under Development by Companies, H1 2015 149

Products under Development by Companies, H1 2015 (Contd..1) 150

Products under Development by Companies, H1 2015 (Contd..2) 151

Products under Development by Companies, H1 2015 (Contd..3) 152

Products under Development by Companies, H1 2015 (Contd..4) 153

Products under Development by Companies, H1 2015 (Contd..5) 154

Products under Development by Companies, H1 2015 (Contd..6) 155

Products under Development by Companies, H1 2015 (Contd..7) 156

Products under Development by Companies, H1 2015 (Contd..8) 157

Products under Development by Companies, H1 2015 (Contd..9) 158

Products under Development by Companies, H1 2015 (Contd..10) 159

Products under Development by Companies, H1 2015 (Contd..11) 160

Products under Development by Companies, H1 2015 (Contd..12) 161

Products under Development by Companies, H1 2015 (Contd..13) 162

Products under Development by Companies, H1 2015 (Contd..14) 163

Products under Development by Companies, H1 2015 (Contd..15) 164

Products under Development by Companies, H1 2015 (Contd..16) 165

Products under Development by Companies, H1 2015 (Contd..17) 166

Products under Development by Companies, H1 2015 (Contd..18) 167

Products under Development by Companies, H1 2015 (Contd..19) 168

Products under Development by Companies, H1 2015 (Contd..20) 169

Products under Development by Companies, H1 2015 (Contd..21) 170

Products under Development by Companies, H1 2015 (Contd..22) 171

Products under Development by Companies, H1 2015 (Contd..23) 172

Products under Development by Companies, H1 2015 (Contd..24) 173

Products under Development by Companies, H1 2015 (Contd..25) 174

Products under Development by Companies, H1 2015 (Contd..26) 175

Products under Development by Companies, H1 2015 (Contd..27) 176

Products under Development by Companies, H1 2015 (Contd..28) 177

Products under Development by Companies, H1 2015 (Contd..29) 178

Products under Development by Companies, H1 2015 (Contd..30) 179

Products under Development by Companies, H1 2015 (Contd..31) 180

Products under Development by Companies, H1 2015 (Contd..32) 181

Products under Development by Companies, H1 2015 (Contd..33) 182

Products under Development by Companies, H1 2015 (Contd..34) 183

Products under Development by Companies, H1 2015 (Contd..35) 184

Products under Development by Companies, H1 2015 (Contd..36) 185

Products under Development by Companies, H1 2015 (Contd..37) 186

Products under Development by Companies, H1 2015 (Contd..38) 187

Products under Development by Companies, H1 2015 (Contd..39) 188

Products under Development by Companies, H1 2015 (Contd..40) 189

Products under Development by Companies, H1 2015 (Contd..41) 190

Products under Development by Companies, H1 2015 (Contd..42) 191

Products under Development by Companies, H1 2015 (Contd..43) 192

Products under Development by Companies, H1 2015 (Contd..44) 193

Products under Development by Companies, H1 2015 (Contd..45) 194

Products under Development by Companies, H1 2015 (Contd..46) 195

Products under Investigation by Universities/Institutes, H1 2015 196

Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 197

Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 198

Products under Investigation by Universities/Institutes, H1 2015 (Contd..3) 199

Products under Investigation by Universities/Institutes, H1 2015 (Contd..4) 200

Products under Investigation by Universities/Institutes, H1 2015 (Contd..5) 201

Products under Investigation by Universities/Institutes, H1 2015 (Contd..6) 202

Products under Investigation by Universities/Institutes, H1 2015 (Contd..7) 203

Products under Investigation by Universities/Institutes, H1 2015 (Contd..8) 204

Products under Investigation by Universities/Institutes, H1 2015 (Contd..9) 205

Products under Investigation by Universities/Institutes, H1 2015 (Contd..10) 206

Breast Cancer - Pipeline by 3-V Biosciences, Inc., H1 2015 207

Breast Cancer - Pipeline by A&G Pharmaceutical, Inc., H1 2015 208

Breast Cancer - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2015 209

Breast Cancer - Pipeline by AB Science, H1 2015 210

Breast Cancer - Pipeline by AbbVie Inc., H1 2015 211

Breast Cancer - Pipeline by AbGenomics International, Inc., H1 2015 212

Breast Cancer - Pipeline by Actinium Pharmaceuticals, Inc., H1 2015 213

Breast Cancer - Pipeline by Adaptimmune Limited, H1 2015 214

Breast Cancer - Pipeline by Advanced Cancer Therapeutics, H1 2015 215

Breast Cancer - Pipeline by Advanced Proteome Therapeutics Corporation, H1 2015 216

Breast Cancer - Pipeline by Advaxis, Inc., H1 2015 217

Breast Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2015 218

Breast Cancer - Pipeline by Aegis Therapeutics, LLC, H1 2015 219

Breast Cancer - Pipeline by Aerpio Therapeutics, Inc., H1 2015 220

Breast Cancer - Pipeline by Aeterna Zentaris Inc., H1 2015 221

Breast Cancer - Pipeline by Affichem, H1 2015 222

Breast Cancer - Pipeline by Aileron Therapeutics, Inc., H1 2015 223

Breast Cancer - Pipeline by Alchemia Limited, H1 2015 224

Breast Cancer - Pipeline by Alethia Biotherapeutics Inc., H1 2015 225

Breast Cancer - Pipeline by Almac Discovery Ltd., H1 2015 226

Breast Cancer - Pipeline by AlphaMab Co., Ltd, H1 2015 227

Breast Cancer - Pipeline by AlphaVax, Inc., H1 2015 228

Breast Cancer - Pipeline by Amarna Therapeutics B.V., H1 2015 229

Breast Cancer - Pipeline by Ambrx, Inc., H1 2015 230

Breast Cancer - Pipeline by Amgen Inc., H1 2015 231

Breast Cancer - Pipeline by Ampio Pharmaceuticals, Inc., H1 2015 232

 

Number of Products under Development for Breast Cancer, H1 2015 103

Number of Products under Development for Breast Cancer - Comparative Analysis, H1 2015 104

Number of Products under Development by Companies, H1 2015 105

Number of Products under Investigation by Universities/Institutes, H1 2015 136

Comparative Analysis by Late Stage Development, H1 2015 145

Comparative Analysis by Clinical Stage Development, H1 2015 146

Comparative Analysis by Early Stage Products, H1 2015 147

Assessment by Monotherapy Products, H1 2015 553

Assessment by Combination Products, H1 2015 554

Number of Products by Top 10 Targets, H1 2015 555

Number of Products by Stage and Top 10 Targets, H1 2015 555

Number of Products by Top 10 Mechanism of Actions, H1 2015 577

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 577

Number of Products by Top 10 Routes of Administration, H1 2015 591

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 591

Number of Products by Top 10 Molecule Types, H1 2015 593

Number of Products by Stage and Top 10 Molecule Types, H1 2015 593